Ghrelin, obesity and atherosclerosis
Само за регистроване кориснике
2012
Аутори
Sudar, EminaSoskić, Sanja
Zarić, Božidarka
Rašić-Milutinović, Zorica
Smiljanić, Katarina
Radak, Đorđe
Mikhailidis, Dimitri
Rizzo, Manfredi
Isenović, Esma
Поглавље у монографији (Објављена верзија)
,
Nova Science Publishers Inc, New York
Метаподаци
Приказ свих података о документуАпстракт
Cardiovascular disease (CVD) is common cause of death in humans and its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality. This inflammatory process, triggered by the presence of lipids in the vascular wall, and encompasses a complex interaction among inflammatory cells, vascular elements, and lipoproteins through the expression of several adhesion molecules and cytokines. Obesity is a risk factor for CVD but this association is not fully understood. Altered levels of obesity related peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence indicates that ghrelin features several cardiovascular activities, including increased myocardial contractility, vasodilatation and protection from myocardial infarction. Recent data demonstrate that ghrelin can i...nfluence important key events in atherogenesis and thus they may play a role in atherosclerosis. In this review we present the latest data from recent animal and clinical studies which focus on a novel approach to ghrelin as a potential therapeutic agent in the treatment of a complex disease like atherosclerosis. Thus, ghrelin may become a new therapeutic target for the treatment of CVD. Further studies are necessary to investigate the potential mechanisms involved in the effects of ghrelin on the cardiovascular system.
Кључне речи:
Ghrelin / obesity / atherosclerosis / cardiovascular diseaseИзвор:
Ghrelin: Production, Action Mechanisms and Physiological Effects, 2012, 111-126Издавач:
- New York : Nova Science Publishers Inc.
Финансирање / пројекти:
Напомена:
- The peer-reviewed version: https://cer.ihtm.bg.ac.rs/handle/123456789/4380
Повезане информације:
- Друга верзија
https://cer.ihtm.bg.ac.rs/handle/123456789/4380
Институција/група
IHTMTY - CHAP AU - Sudar, Emina AU - Soskić, Sanja AU - Zarić, Božidarka AU - Rašić-Milutinović, Zorica AU - Smiljanić, Katarina AU - Radak, Đorđe AU - Mikhailidis, Dimitri AU - Rizzo, Manfredi AU - Isenović, Esma PY - 2012 UR - https://cer.ihtm.bg.ac.rs/handle/123456789/4379 AB - Cardiovascular disease (CVD) is common cause of death in humans and its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality. This inflammatory process, triggered by the presence of lipids in the vascular wall, and encompasses a complex interaction among inflammatory cells, vascular elements, and lipoproteins through the expression of several adhesion molecules and cytokines. Obesity is a risk factor for CVD but this association is not fully understood. Altered levels of obesity related peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence indicates that ghrelin features several cardiovascular activities, including increased myocardial contractility, vasodilatation and protection from myocardial infarction. Recent data demonstrate that ghrelin can influence important key events in atherogenesis and thus they may play a role in atherosclerosis. In this review we present the latest data from recent animal and clinical studies which focus on a novel approach to ghrelin as a potential therapeutic agent in the treatment of a complex disease like atherosclerosis. Thus, ghrelin may become a new therapeutic target for the treatment of CVD. Further studies are necessary to investigate the potential mechanisms involved in the effects of ghrelin on the cardiovascular system. PB - New York : Nova Science Publishers Inc. T2 - Ghrelin: Production, Action Mechanisms and Physiological Effects T1 - Ghrelin, obesity and atherosclerosis SP - 111 EP - 126 UR - https://hdl.handle.net/21.15107/rcub_cherry_3920 ER -
@inbook{ author = "Sudar, Emina and Soskić, Sanja and Zarić, Božidarka and Rašić-Milutinović, Zorica and Smiljanić, Katarina and Radak, Đorđe and Mikhailidis, Dimitri and Rizzo, Manfredi and Isenović, Esma", year = "2012", abstract = "Cardiovascular disease (CVD) is common cause of death in humans and its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality. This inflammatory process, triggered by the presence of lipids in the vascular wall, and encompasses a complex interaction among inflammatory cells, vascular elements, and lipoproteins through the expression of several adhesion molecules and cytokines. Obesity is a risk factor for CVD but this association is not fully understood. Altered levels of obesity related peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence indicates that ghrelin features several cardiovascular activities, including increased myocardial contractility, vasodilatation and protection from myocardial infarction. Recent data demonstrate that ghrelin can influence important key events in atherogenesis and thus they may play a role in atherosclerosis. In this review we present the latest data from recent animal and clinical studies which focus on a novel approach to ghrelin as a potential therapeutic agent in the treatment of a complex disease like atherosclerosis. Thus, ghrelin may become a new therapeutic target for the treatment of CVD. Further studies are necessary to investigate the potential mechanisms involved in the effects of ghrelin on the cardiovascular system.", publisher = "New York : Nova Science Publishers Inc.", journal = "Ghrelin: Production, Action Mechanisms and Physiological Effects", booktitle = "Ghrelin, obesity and atherosclerosis", pages = "111-126", url = "https://hdl.handle.net/21.15107/rcub_cherry_3920" }
Sudar, E., Soskić, S., Zarić, B., Rašić-Milutinović, Z., Smiljanić, K., Radak, Đ., Mikhailidis, D., Rizzo, M.,& Isenović, E.. (2012). Ghrelin, obesity and atherosclerosis. in Ghrelin: Production, Action Mechanisms and Physiological Effects New York : Nova Science Publishers Inc.., 111-126. https://hdl.handle.net/21.15107/rcub_cherry_3920
Sudar E, Soskić S, Zarić B, Rašić-Milutinović Z, Smiljanić K, Radak Đ, Mikhailidis D, Rizzo M, Isenović E. Ghrelin, obesity and atherosclerosis. in Ghrelin: Production, Action Mechanisms and Physiological Effects. 2012;:111-126. https://hdl.handle.net/21.15107/rcub_cherry_3920 .
Sudar, Emina, Soskić, Sanja, Zarić, Božidarka, Rašić-Milutinović, Zorica, Smiljanić, Katarina, Radak, Đorđe, Mikhailidis, Dimitri, Rizzo, Manfredi, Isenović, Esma, "Ghrelin, obesity and atherosclerosis" in Ghrelin: Production, Action Mechanisms and Physiological Effects (2012):111-126, https://hdl.handle.net/21.15107/rcub_cherry_3920 .